Q1 2023 13F Holders as of 3/31/2023
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share (the "Shares")
-
Shares outstanding
-
93.8M
-
Number of holders
-
126
-
Total 13F shares, excl. options
-
55M
-
Shares change
-
+229K
-
Total reported value, excl. options
-
$884M
-
Value change
-
+$109K
-
Put/Call ratio
-
0
-
Number of buys
-
76
-
Number of sells
-
-41
-
Price
-
$16.06
Significant Holders of Crinetics Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (the "Shares") (CRNX) as of Q1 2023
142 filings reported holding CRNX - Crinetics Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (the "Shares") as of Q1 2023.
Crinetics Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (the "Shares") (CRNX) has 126 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 55M shares
of 93.8M outstanding shares and own 58.69% of the company stock.
Largest 10 shareholders include DRIEHAUS CAPITAL MANAGEMENT LLC (5.29M shares), BlackRock Inc. (3.96M shares), ORBIMED ADVISORS LLC (3.95M shares), WELLINGTON MANAGEMENT GROUP LLP (3.64M shares), PERCEPTIVE ADVISORS LLC (3.55M shares), BVF INC/IL (2.74M shares), VANGUARD GROUP INC (2.69M shares), Bain Capital Life Sciences Investors, LLC (2.31M shares), STATE STREET CORP (2.22M shares), and BRAIDWELL LP (2.02M shares).
This table shows the top 126 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.